Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
The study is designed to assess whether glufosfamide provides additional survival benefit as
compared to bolus 5-FU in patients with metastatic pancreatic cancer who have already
progressed or failed therapy on a gemcitabine based first line regimen.